Member Info for Dr_Horrible

AI says no to pomace. It says they take the jelly stuff out before it is pomace. Either way, I think it is derived from what would potentially be waste.

So the only requirement for the tomato paste is that it is from a 'cold break'. So that can be tomato pomace then, just not heated.

In the processing of tomatoes, "Cold Break" and "Hot Break" refer to two distinct methods of pre-heating chopped tomatoes before further processing into products like pastes, purees, and sauces. The main difference lies in the temperature at which the tomatoes are heated and the impact this has on the enzymes, particularly pectinases, which affect the final product's viscosity and characteristics.

1. Hot Break (HB)

Temperature: Tomatoes are rapidly heated to high temperatures, typically between 85°C to 100°C (185°F to 212°F), immediately after chopping. Some methods even go up to 105°C.

2. Cold Break (CB)

Temperature: Tomatoes are heated at relatively lower temperatures, typically between 65°C to 75°C (149°F to 167°F), after chopping

Yeh the cost of the tomatoes is very low I believe, but the main cost is making that into FF and all the associated testing to ensure quality.

I think many years ago that Moon said it was derived from pomace, a by-product of the tomato industry.

We had the same opinion with similar articles 12 months ago.

New .com site, much improved and accessible from the UK.

FF mention: https://www.by-health.com/en/about-research/?#byhealth

Only 110 days until the next update :(

Ah I missed that, thanks.

The product is being launched in Singapore. We don’t know if there will be a wider distribution yet, The product contain 75mg of FF per dose. The graphics in the presentation are not the standard ones used by most DSM customers, so it may be they bought direct, but that’s just a guess based on little evidence.

Customers of BH will be able to use the claim by buying FF from BH.

Some more positive thoughts.

When a Chinese company wants to submit a Functional Food for SAMR Registration ('Big Blue Hat') for use of an existing health claim on the register, it would involve clinical trials in China, extensive safety evaluations, and efficacy testing.

My thought is that when the Platelet Aggregation claim is added to the register, it will be restricted to By-Health FF for 5 years. With Fruitflow being a single product from a single source (PXS), and already subject to safety and quality standards, there would be little value in each BH business customer carrying out clinical trials to prove the platelet aggregation claim. So I see it that the main aim of the Blue Hat evaluation for those products will be for the non-Fruitflow ingredients quality and safety, along with the packaging.

This should speed up the process for a company to achieve Blue Hat registration of their product where it includes the platelet aggregation health claim and It will also reduce the risk of it not being approved. This makes it more attractive for companies.

When will it be approved? Well.... all my guesses have passed. I await the end of September update and then...

https://www.youtube.com/watch?v=Pg9EWZUwBw0

A while back we found a DSM slide that showed FF as a gut health ingredient. At the time I could not find it anywhere on the DSM website. It’s now there under Discover Biotics.

https://www.dsm-firmenich.com/hfg-science

If only we knew what FF sales were.

It’s certainly a risk that BH make all the money and little is left for PXS. However, the spirit of the agreement is supposed to be a partnership that benefits both companies. That’s what they said.

As for patents holding things up, I doubt it. They can’t launch everything at once, so there will be an order. I would assume they are covered on their initial releases. The patents may be for products that BH will sell, or they could be for products that they will supply to other companies. They developed a wide range of products, keep the best ones for themselves and offer up the remaining ones to other companies.

I used 60% because Meta AI advised me that it was what you expect for the industry. Therefore it is the best and only info I have. When I have bought and sold goods, I have always at least doubled up, so it felt about right. We have no idea what the reality is.

When BH make their initial order we will be well into profitability. BH are a very large company themselves (9% market share) and will be launching many products, using FF as the platform for their heart health products (BP, lipids, flow), but also for other things like memory, wound healing, fertility, sports performance/recovery etc. On top of that, a large number of multinational companies have agreed to help them commercialise FF in China. On top of that, I would say it is likely that the Chinese state will also provide support, as BH have already stated that they are doing this to address the risks highlighted in the HC2030 policy. On top of that, beef sausages of Ershang Meat Co :)

I am guessing that the first order will be somewhere in the range of £4m to £6m and the profit for PXS on that will be about 60%. Then there will be massive growth ahead.

We don't have enough information to give an informed guess, so it's just my feeling, which may be totally wrong.

Also remembering that in China the blood pressure and lipids/cholesterol products will be based on 300mg of FF in line with their clinic trials. They will need to stick to their trial amounts in order to use the associated health claim. DSM are working with globals and I assume they will be launching products based on 300mg FF in line with the gut health clinical trial.

This means that no only are we getting major players, but also using 2 standard doses per day.

Don’t forget that we have truly global companies, the likes of Nestle, Danone, Reckitt, PepsiCo, General Mills, Abbott, etc. Hopefully we’ll see a launch this year.

If there was to be an offer for purchase of PXS, how would we know if we were getting a good deal? It feels like this is going to be massive (that’s what she said). We have no idea of the plan or the forecasts. It’s only the research on here that tells us what a big deal FF could be.

The costs will be awarded to PXS, they were explicitly mentioned in the original case documents.